Navigation Links
CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
Date:5/3/2012

KING OF PRUSSIA, Pa. and MARBURG, Germany, May 3, 2012 /PRNewswire/ -- CSL Behring announced today that it has initiated an international phase I/II study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor (C1-INH) concentrate in patients with hereditary angioedema (HAE). Part of the COMPACT (Clinical Studies for Optimal Management in Preventing Angioedema with Low-Volume Subcutaneous C1-inhibitor Replacement Therapy) program, the study will evaluate the pharmacokinetics, pharmacodynamics and safety of various doses of this presentation of C1-INH.

"We're enormously pleased that a range of therapy options is now available to treat HAE," said Bruce Zuraw, MD, Professor of Medicine at the University of California, San Diego, USA, and Chairman of the Steering Committee for the COMPACT program. "Yet, we know that a significant number of patients would prefer a preventive therapy that does not require intravenous infusions and that might offer fewer side effects than currently available treatments. We are confident this study will guide us in the development of this novel method of using C1-esterase inhibitor replacement for the routine prevention of HAE attacks."

The open-label study will enroll adult patients with HAE type I or II. After an initial intravenous injection of C1-INH, each participant will be assigned to receive a single subcutaneous injection of the volume-reduced formulation of C1-INH twice a week for four weeks. Subjects will participate in two such periods with two different doses of volume-reduced C1-INH. Throughout the study, researchers will monitor C1-INH levels in the blood, as well as assess the safety and tolerability of the formulation at different doses.

"As a pioneer in the development of subcutaneous immunoglobulin therapy, we are excited to apply our expertise and experience in the treatment of hereditary angioedema," said Russell
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CSL Behring Renews Pledge to Provide Significant Funding and Donated Coagulation Factor to World Federation of Hemophilia Over 3-Year Period
2. CSL Behring Announces First Patient Treated in Phase III Study of Fibrinogen Concentrate (Human)(FCH) to Control Bleeding During Aortic Aneurysm Surgery
3. CSL Behring Recognized as a "Pioneer" By European Organisation for Rare Diseases (EURORDIS)
4. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
5. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
6. CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
7. CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
8. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
9. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
10. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
11. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Colo. , Feb. 26, 2015 ... installation Company specializing in commercial indoor cannabis cultivation ... continued evolution from start-up to fast-paced manufacturing and ... Tom Bollich , current Director and CEO, will ... "I,m extremely proud of what the team has ...
(Date:2/26/2015)... CITY , Feb. 26, 2015  Great Basin ... launched a "best efforts" follow-on offering of up to ... of one share of Series E preferred stock and ... preferred stock will be convertible into four shares of ... exercisable into one share of common stock at an ...
(Date:2/26/2015)... , February 26, 2015 ABIVAX, ... and human vaccines, today announced that it has dosed in ... a Phase IIb/III clinical trial of ABX203 which is taking ... region. The study is designed to assess whether ABX203 ... hepatitis B (CHB) via controlling viral load for a much ...
Breaking Medicine Technology:Surna, Inc. Announces Senior Leadership Changes 2Surna, Inc. Announces Senior Leadership Changes 3Surna, Inc. Announces Senior Leadership Changes 4Great Basin Scientific, Inc. Announces Commencement of Public Offering 2Great Basin Scientific, Inc. Announces Commencement of Public Offering 3ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 2ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 3ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 4ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 5
... SAN ANTONIO, Feb. 28, 2011 Advanced Cell ... its clinical study utilizing RNAscope™ technology to detect ... specimens of head and neck cancer. HPV status ... predictive of patient outcome and highly concordant with ...
... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today ... chief executive officer, is scheduled to present a company ... March.  Details of each conference are as follows:Citi Global ... ETLocation:  New York, NY Cowen and Company 31st Annual ...
Cached Medicine Technology:ACD Announces Clinical Study Results Using its RNAscope™ Technology 2ACD Announces Clinical Study Results Using its RNAscope™ Technology 3Rigel to Present at Three Upcoming Investor Conferences 2
(Date:2/26/2015)... Florida (PRWEB) February 26, 2015 Miami auto ... of the website with a new, useful addition by making ... deals with recall issues. , “Given the fact that last ... numbers, I think that keeping drivers - especially those car ... – well informed on recall issues is important.” – Personal ...
(Date:2/26/2015)... Colorado (PRWEB) February 26, 2015 As ... millions are looking for deeper meaning, more substantial roles ... question – how do I live a life that ... 10th round of Younger Next Year Total Immersion ... revealed. This program boasts unbelievable results and jump-starts a ...
(Date:2/26/2015)... 26, 2015 When Cosmetic Town launched ... vision that included, what will soon be, the cornerstone ... information. The plethora of insight that will be accessible ... the Editorial Team has maintained during its existence. Users ... articles on treatments by visiting the Cosmetic Town Journal’s ...
(Date:2/26/2015)... 2015 Thousands of people in local ... powerful progress for the Muscular Dystrophy Association during the ... and awareness that will help save and improve the ... “MDA Muscle Walk events unite and rally communities to ... to move are compromised — including everyday abilities like ...
(Date:2/26/2015)... SpendWell Health, an online marketplace for ... first customer today, opening its doors to Cambia ... , SpendWell delivers the next generation of online ... transparency with e-commerce. SpendWell’s unique platform shows actual ... services and allows shoppers to buy those services ...
Breaking Medicine News(10 mins):Health News:Auto Recalls Additional Feature, Sean M. Cleary Miami Auto Accident Lawyer 2Health News:The Aspen Club on Actively Aging: Telling a New Story on Aging 2Health News:Cosmetic Town has now Recreated Itself by Adding New Features 2Health News:MDA Kicks-Off Annual Muscle Walk Season in Local Communities Nationwide to Fight Back Against Muscle Disease 2Health News:MDA Kicks-Off Annual Muscle Walk Season in Local Communities Nationwide to Fight Back Against Muscle Disease 3Health News:SpendWell Launches New Online Health Care Marketplace to Large Employer Group 2Health News:SpendWell Launches New Online Health Care Marketplace to Large Employer Group 3
... Healthcare consumers have role to play in preventing, recovering from ... ... take several,steps to prevent the theft of their medical identity and ... medical,identity theft, according to a new practice brief, "Mitigating Medical,Identity Theft," ...
... BRUNSWICK, N.J., July 8 Johnson & Johnson,will ... 8:30 a.m. (Eastern,Time) on Tuesday, July 15, 2008, ... and Chief Financial Officer, and Louise,Mehrotra, Vice President, ... and other interested parties may access the broadcast ...
... burden and amount of suffering associated with mental ... health care systems in Europe today. This challenge ... of mental disorders. Important factors are their persistent ... socioeconomic changes currently taking place, and, finally, the ...
... think about what you eat, study finds, , , TUESDAY, July ... with a food diary can double your weight loss, a ... has been around a long time, this latest research offers ... co-author Dr. Victor J. Stevens, a senior investigator at Kaiser ...
... 8 Michael E. Kerr, MD,Director of the Bowen ... in private practice, will address the topic of autism ... one of the most widely,discussed and intensively researched clinical ... a dramatic increase in the,number of children diagnosed to ...
... Home Medical,Equipment, Inc. (OTC: SHOM) announced today that its ... the second quarter of 2008,compared to the first quarter ... stated, "We have focused a significant portion of our ... Medical Staffing. We are,very excited to see that our ...
Cached Medicine News:Health News:Mitigating Medical Identity Theft: AHIMA Journal Provides Patient Tools to Secure Health Information 2Health News:Mitigating Medical Identity Theft: AHIMA Journal Provides Patient Tools to Secure Health Information 3Health News:21st Congress of the College of Neuropsychopharmacology, Aug. 30-Sept. 3, 2008, Spain 2Health News:21st Congress of the College of Neuropsychopharmacology, Aug. 30-Sept. 3, 2008, Spain 3Health News:21st Congress of the College of Neuropsychopharmacology, Aug. 30-Sept. 3, 2008, Spain 4Health News:21st Congress of the College of Neuropsychopharmacology, Aug. 30-Sept. 3, 2008, Spain 5Health News:21st Congress of the College of Neuropsychopharmacology, Aug. 30-Sept. 3, 2008, Spain 6Health News:21st Congress of the College of Neuropsychopharmacology, Aug. 30-Sept. 3, 2008, Spain 7Health News:21st Congress of the College of Neuropsychopharmacology, Aug. 30-Sept. 3, 2008, Spain 8Health News:Keep a Food Diary, Lose Twice as Much Weight 2Health News:Southern Home Medical Reports Its Encore Medical Staffing Division Increases Revenues by 63% 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: